European Journal of Molecular & Clinical Medicine

A novel N-(5-oxo-2-phenylimidazolidin-1-yl)-4-(3,4-dihydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (1) was synthesized using Biginelli reaction at room temperature. The dual heterocyclic compound 1 was characterized using the analytical techniques such as FT-IR, 1H & 13C-NMR, Mass analysis, UV-visible and fluorescent spectroscopic system. The data on charge density was used to explain the characteristics of molecular systems. In addition, in the form of the complete and partial density of states, the HOMO-LUMO energy gap, electrostatic potential map and some quantum chemical insights have been obtained. Furthermore, to demonstrate the possible applications of dihydropyrimidinone 1 in nonlinear optics the polarizability and first hyperpolarizability were measured. Molecular docking is also determined in order to illustrate the overexpression of estrogen receptor in 80 % of 2J9M protein. The compound 1 was subjected for its antioxidant (ABTS) and anticancer activity (DPPH) by in-vitro analyses and found with substantial antioxidant activity.

The chemical structure of the newly synthesized compound Ethyl-6-methyl-2-oxo-4-(3,4,5-trichlorophenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate 4 was confirmed by elemental analysis, 1H NMR, 13C NMR, and ESI-HRMS spectral data. In addition, in the form of the complete and partial density of states, the HOMO-LUMO energy gap, and electrostatic potential map, etc., some quantum chemical insights have been obtained. Furthermore, to demonstrate the possible applications of dihydropyrimidinone 4 in nonlinear optics, the polarizability and first hyperpolarizability were measured. Molecular docking is also determined in order to illustrate the over expression of estrogen receptor in 92 % of 2J9M protein. The antitumor activity of these compound was evaluated on breast cancer (MCF-7) cell lines by a cell viability assay utilizing the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Although with varying degrees, a significant growth inhibitory and cytotoxic effect was observed on MCF-7 cancer cell line. The tested compound 4, was active against MCF-7 cell line (in-vitro analysis) with IC50 values of 45 μM. The compound was subjected for the DPPH & ABTS tests, evaluated its antioxidant activity. With further characterization, mechanism of biological action, this compound 4 shall be a potential / useful candidate as anticancer drug.